Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

More than a million Americans have died from overdoses during the opioid epidemic

Deaths due to drug overdose have topped a million for the first time since the Centers for Disease Control and Prevention began collecting data on the problem more than two decades ago.

A study released Thursday by the National Center for Health Statistics, a division of the CDC, found that 932,364 people died in the U.S. from fatal overdoses from 1999 through 2020.

Separate preliminary data from the CDC shows another 100,000 drug deaths expected in 2021.

Unlike the COVID-19 pandemic, which hit elderly Americans hardest, researchers found drug deaths have risen fastest among the young and middle-aged adults struggling with addiction.

“Among adults aged 35–44, the age group with the highest rates, drug overdose deaths increased 33% from 2019 to 2020,” the report found. Men are also more vulnerable than women, it said.

Source: NPR

https://www.npr.org/2021/12/30/1069062738/more-than-a-million-americans-have-died-from-overdoses-during-the-opioid-epidemi

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!